Lixisenatide

Drug Profile

Lixisenatide

Alternative Names: Adlyxin; AQVE-10010; AVE-0010; AVE0100; Lyxumia; ZP-10; ZP10A peptide

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Zealand Pharma
  • Developer Sanofi; sanofi-aventis
  • Class Antihyperglycaemics; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Type 1 diabetes mellitus

Most Recent Events

  • 27 Jan 2017 Sanofi terminates phase II trial in Type-2 diabetes mellitus in Italy (NCT02274740)
  • 25 Oct 2016 Sanofi enter into a collaboration agreement with Myriad RMB, a wholly-owned subsidiary of Myriad Genetics to perform biomarker analysis for the ELIXA trial
  • 25 Oct 2016 Sanofi plans a phase IV trial for Type 2 diabetes mellitus (add-on treatment to basal insulin) in Lebanon (NCT02941367)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top